| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/02/2010 | CA2494583C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/02/2010 | CA2454830C Substituted urea neuropeptide y y5 receptor antagonists |
| 02/02/2010 | CA2436752C Bifidobacteria and preparations containing them |
| 02/02/2010 | CA2410305C Preparations comprising combinations of enzyme inhibitors, and the use thereof |
| 02/02/2010 | CA2407428C Hydantoin-containing glucokinase activators |
| 02/02/2010 | CA2401832C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 02/02/2010 | CA2396158C Dipeptide nitrile cathepsin k inhibitors |
| 02/02/2010 | CA2315205C Substituted 2-aryl-4-amino-quinazolines, methods for the prodution ans use thereof as medicaments |
| 02/02/2010 | CA2294809C Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same |
| 02/02/2010 | CA2160898C Alimentative infusion liquids for administration through peripheral vein |
| 01/28/2010 | WO2010011926A2 A novel betaine cocrystal of epalrestat |
| 01/28/2010 | WO2010011922A2 Novel crystalline salts of epalrestat |
| 01/28/2010 | WO2010011879A2 Methods and compositions for treating and preventing autoimmune diseases |
| 01/28/2010 | WO2010011836A2 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| 01/28/2010 | WO2010011597A2 Treatment of obesity and related disorders |
| 01/28/2010 | WO2010011331A2 Compositions and methods related to sirt1 function |
| 01/28/2010 | WO2010011319A2 Magnetic heating for drug delivery and other applications |
| 01/28/2010 | WO2010011147A1 Indole compounds |
| 01/28/2010 | WO2010010949A1 Lipase inhibitor |
| 01/28/2010 | WO2010010887A1 Tissue expression promoter |
| 01/28/2010 | WO2010010786A1 Enhancer of expression of β3-adrenergic receptor |
| 01/28/2010 | WO2010010579A1 Multiple unit dosage form of niacin |
| 01/28/2010 | WO2010010531A2 Composition for controlling increase in blood glucose |
| 01/28/2010 | WO2010010383A1 Treatment of obesity |
| 01/28/2010 | WO2010010174A1 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use |
| 01/28/2010 | WO2010010112A2 Construct and method for the internalization of cargo molecules into a cell |
| 01/28/2010 | WO2010010014A1 4,5-dihydro-oxazol-2-yl derivatives |
| 01/28/2010 | WO2010009872A1 Modified cck peptides |
| 01/28/2010 | WO2010009775A1 Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases |
| 01/28/2010 | WO2010009619A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 01/28/2010 | WO2010009618A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 01/28/2010 | WO2009136396A3 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| 01/28/2010 | WO2009090656A3 Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| 01/28/2010 | WO2009027849A3 Guava extract |
| 01/28/2010 | US20100022783 Cyclohexanecarboxylic acid compound |
| 01/28/2010 | US20100022643 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 01/28/2010 | US20100022635 Heat shock protein 90 inhibitor dosing methods |
| 01/28/2010 | US20100022634 Laidlomycin compositions and methods |
| 01/28/2010 | US20100022630 Method of treatment using fatty acid synthesis inhibitors |
| 01/28/2010 | US20100022629 Dietary Methods and Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species |
| 01/28/2010 | US20100022628 Alternative oxidase and uses thereof |
| 01/28/2010 | US20100022620 Epitope reduction therapy |
| 01/28/2010 | US20100022619 Compositions and their uses directed to ptpr alpha |
| 01/28/2010 | US20100022611 1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents |
| 01/28/2010 | US20100022598 Substituted inmidazoles as bombesin receptor subtype-3 modulators |
| 01/28/2010 | US20100022592 Thiazole derivatives as modulators of g protein-coupled receptors |
| 01/28/2010 | US20100022591 Piperidine gpcr agonists |
| 01/28/2010 | US20100022589 Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| 01/28/2010 | US20100022582 Tetrahydroisoquinoline Compound and Medicinal Use Thereof |
| 01/28/2010 | US20100022572 Novel spiro compound and medicine comprising the same |
| 01/28/2010 | US20100022556 Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin |
| 01/28/2010 | US20100022554 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| 01/28/2010 | US20100022544 Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof |
| 01/28/2010 | US20100022528 Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| 01/28/2010 | US20100022524 Tricyclic tetrahydroquinoline antibacterial agents |
| 01/28/2010 | US20100022520 Malonyl-coa acetyltransferase inhibitors against antibiotic resistant bactertia |
| 01/28/2010 | US20100022519 Heterocyclic-substituted piperidine compounds and the uses thereof |
| 01/28/2010 | US20100022513 Organic compounds |
| 01/28/2010 | US20100022502 Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| 01/28/2010 | US20100022498 Steroids as agonists for fxr |
| 01/28/2010 | US20100022496 Galenical form for the administration of active ingredients by transmucous means |
| 01/28/2010 | US20100022486 Compounds |
| 01/28/2010 | US20100022474 Polymer Controlled Induced Viscosity Fiber System and Uses Thereof |
| 01/28/2010 | US20100022462 Appetite suppressant and colon cleansing composition |
| 01/28/2010 | US20100022455 Therapeutic agents comprising elastin-like peptides |
| 01/28/2010 | US20100022451 Use of infant formula with reduced protein content |
| 01/28/2010 | US20100022448 Peptides |
| 01/28/2010 | US20100022446 Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
| 01/28/2010 | US20100021976 Production of polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs |
| 01/28/2010 | US20100021568 Anti-Obesity Product And Its Method Of Preparation |
| 01/28/2010 | US20100021567 Peganine Isolated from Anisotes Trisulcus L. as a Smoking Deterrent and Anorxigenic Agent |
| 01/28/2010 | US20100021564 Om vitamin formula |
| 01/28/2010 | US20100021555 Compositions containing high omega-3 and low saturated fatty acid levels |
| 01/28/2010 | US20100021539 Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation |
| 01/28/2010 | US20100021535 Light-stabilized soft capsule formulations |
| 01/28/2010 | US20100021495 Diet product comprising alginate |
| 01/28/2010 | US20100021487 Vaccines and methods for controlling adiposity |
| 01/28/2010 | US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control |
| 01/28/2010 | US20100021469 Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology |
| 01/28/2010 | US20100021462 Gasp1: a follistatin domain containing protein |
| 01/28/2010 | US20100021445 Agent for reducing visceral fat |
| 01/28/2010 | US20100021435 Pancreatic islet-like cells |
| 01/28/2010 | US20100021430 Horse feed and treatment methods |
| 01/28/2010 | US20100021393 Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate |
| 01/28/2010 | US20100021386 Treatment, prevention,and reversal of alcohol-induced liver disease |
| 01/28/2010 | CA2732228A1 Methods and compositions for treating and preventing autoimmune diseases |
| 01/28/2010 | CA2731849A1 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| 01/28/2010 | CA2731242A1 Compositions and methods related to sirt1 function |
| 01/28/2010 | CA2730208A1 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use |
| 01/28/2010 | CA2729998A1 Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 01/28/2010 | CA2728480A1 4,5-dihydro-oxazol-2-yl derivatives |
| 01/27/2010 | EP2147910A1 Novel lipid compounds |
| 01/27/2010 | EP2147683A1 Construct and method for the internalization of cargo molecules into a cell |
| 01/27/2010 | EP2147681A1 Compositions and methods for treating lysosomal storage disease |
| 01/27/2010 | EP2147673A1 Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| 01/27/2010 | EP2146997A1 Substituted furo[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators |
| 01/27/2010 | EP2146952A1 N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| 01/27/2010 | EP2146741A2 Medicaments and methods to treat autoimmune disease and cancer |
| 01/27/2010 | EP2146726A1 Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| 01/27/2010 | EP1554286B1 Fused heterocyclic isoxazoline derivatives and their use as anti-depressants |